Atterocor changes name to Millendo, gets $62mm in Series B

Atterocor changed its name to Millendo Therapeutics Inc. to reflect its focus on endocrine therapies, and raised $62mm in Series B financing. New Enterprise Associates led and was joined by other new backers Roche Venture Fund, Adams Street Partners, Altitude Life Science Ventures, Longwood Fund, and Renaissance Venture Capital Fund, and returning shareholders Frazier Healthcare Partners, Osage University Partners, 5AM Ventures, and the Regents of the University of Michigan. A representative from Roche Venture Fund and NEA will join Millendo’s board. Concurrent with the round, Millendo acquired exclusive rights to AstraZeneca's Phase II AZD4901 (renamed MLE4901) for polycystic ovary syndrome.